Astellas, Seattle Genetics Break Ground With US ADC Approval
Earlier-Stage Combo Also Shows Big Promise
Executive Summary
Co-developers gain nod for novel antibody-drug conjugate that provides new option for patients with advanced form of bladder cancer.
You may also be interested in...
Seagen, Astellas Data Support Broader Indication For Padcev/Keytruda Combo
With accelerated approval in advanced urothelial cancer, the sponsors now have data that could support full approval.
Seagen CEO Search Under Way As Longtime Leader Siegall Resigns In Scandal
Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.
Seagen/Genmab's Tivdak Set To Take On Merck’s Keytruda
Accelerated approval of Tivdak in recurrent or metastatic cervical cancer brings Seagen’s fourth cancer therapy and third antibody-drug conjugate to market. Merck is advancing Keytruda in r/mCC as well.